David Ruggiero, DPM
Foot & Ankle Surgery · Riverside, RINPI 1447214291
Payments from drug & device makers
Across 446 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$4K
- Biotissue Holdings Inc.$3K
- Treace Medical Concepts, Inc.$2K
- Acell, Inc.$1K
- Orthofix Medical, Inc.$882
- Polynovo North America LLC$650
- plus $5K from 32 others
What the payments were for
- Speaking & faculty fees$1031%
- Travel & lodging$1,63210%
- Food & beverage$14,11289%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 162 | $4,220 |
| Biotissue Holdings Inc. | 93 | $2,570 |
| Treace Medical Concepts, Inc. | 9 | $1,521 |
| Acell, Inc. | 12 | $1,118 |
| Orthofix Medical, Inc. | 32 | $882 |
| Polynovo North America LLC | 14 | $650 |
| Paratek Pharmaceuticals, Inc. | 17 | $571 |
| Organogenesis Inc. | 10 | $493 |
| Integra Lifesciences Corporation | 16 | $458 |
| Musculoskeletal Transplant Foundation Inc. | 5 | $415 |
| Kerecis Limited | 3 | $377 |
| Misonix Inc | 11 | $309 |
| Zimmer Biomet | 5 | $282 |
| Stryker(2 entities) | 4 | $250 |
| Next Science LLC | 3 | $195 |
| Osiris Therapeutics Inc. | 5 | $184 |
| Innovation Technologies Inc | 1 | $170 |
| Bioventus LLC | 3 | $131 |
| Cardiovascular Systems Inc. | 1 | $123 |
| AstraZeneca | 5 | $119 |
| Lifenet Health | 5 | $98 |
| Novartis | 1 | $89 |
| Pfizer | 2 | $81 |
| Medtronic | 1 | $70 |
| Hikma Pharmaceuticals USA | 3 | $67 |
| Optinose US, Inc. | 4 | $57 |
| KCI USA, Inc. | 3 | $55 |
| AbbVie | 3 | $52 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Medline Industries LP | 2 | $33 |
| Convatec Inc. | 2 | $33 |
| Nevro Corp. | 1 | $28 |
| Biowound Solutions, Inc. | 1 | $27 |
| Reapplix Inc. | 1 | $23 |
| Amgen | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $16 |
| Mimedx Group, Inc. | 1 | $15 |
| Sebela Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stravix$1,180
- Lapiplasty System$976
- Grafix$497
- NEOX$406
- CLARIX$406
- GrafixPL$332
- STRAVIX PL$271
- Kerecis Omega3 Wound$265
- TMC NANOPLASTY SYSTEM$261
- Grafix PRIME$241
- GRAFIX PL$230
- Apligraf$225
- NUZYRA$211
- Irrisept$170
- Novosorb BTM$170
- Oasis$145
- Physio-Stim$129
- Physio-Stim Osteogenesis Stimulator$125
- Peripheral Orbital Atherectomy System$123
- Alps Plates and Instruments$116
How this compares
$15,848 in reported general payments places this provider in the 85th percentile of 58 foot & ankle surgery providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EucrisaCrisaborole | 11 | $7,945 |
| SantylCollagenase Clostridium Hist. | 22 | $6,703 |
| Ammonium Lactate | 65 | $1,106 |
| Terbinafine Hcl | 86 | $670 |
| Ketoconazole | 31 | $505 |
| Cephalexin | 17 | $336 |
| Gabapentin | 20 | $323 |
| Ibuprofen | 20 | $231 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $167 |
| Doxycycline Hyclate | 24 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEucrisa | $81 | $7,94511 claims |
| Smith+NephewSantyl | $4,220 | $6,70322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 foot & ankle surgery providers in Rhode Island.
Other foot & ankle surgery in Riverside
- David GreenbergRiverside$6K
- Christopher DigiovanniProvidence$669K
- Anthony MechrefeWarwick$92K
- Douglas GlodEast Providence$74K
- Matthew LawrencePawtucket$53K
- Michal SzparaPawtucket$52K
- Michael ReuterBristol$34K
- Jason TartaglioneWarwick$21K
- Brian PontarelliProvidence$15K
- James AppletonPawtucket$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.